TLX.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 02:10):

Stats
Today's Volume	1.74M
Average Volume	1.17M
Market Cap	4.92B
EPS	$0 ( 2024-02-21 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	744.00
ATR14	$0.0100 (0.07%)

Volume Correlation

Long: 0.10 (neutral)

Short: -0.64 (weak negative)

Signal:(44.647) Neutral

Telix Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Telix Pharmaceuticals Correlation - Currency/Commodity

0.74
( moderate )

-0.19
( neutral )

0.00
( neutral )

0.67
( moderate )

-0.41
( neutral )

-0.71
( moderate negative )

Telix Pharmaceuticals Financials

Annual	2023
Revenue:	$496.66M
Gross Profit:	$308.50M (62.12 %)
EPS:	$0.0163

Q4	2023
Revenue:	$281.71M
Gross Profit:	$223.98M (79.50 %)
EPS:	$0.0603

Q2	2023
Revenue:	$220.83M
Gross Profit:	$90.81M (41.12 %)
EPS:	$-0.0451

Q4	2022
Revenue:	$136.05M
Gross Profit:	$44.89M (33.00 %)
EPS:	$-0.100

Financial Reports:

No articles found.

Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.